TG Therapeutics schedules Q1 2026 earnings call for May 6 with CEO Michael Weiss.

TG Therapeutics, a biotech company focused on B-cell disease treatments, announced a conference call on May 6, 2026, at 8:30 AM ET to discuss its first quarter 2026 financial results and business outlook. CEO Michael S. Weiss will lead the call, which investors can join via phone or webcast. The company recently received FDA approval for BRIUMVI® to treat relapsing multiple sclerosis and continues to advance its clinical trials. This call will provide insights into the company's performance and future plans for 2026.